2,716 results on '"Gladman, Dafna D"'
Search Results
2. Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort
- Author
-
David, Trixy, Su, Li, Cheng, Yafeng, Gordon, Caroline, Parker, Benjamin, Isenberg, David, Reynolds, John A, Bruce, Ian N, Hanly, John G, Bae, Sang-Cheol, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Bernatsky, Sasha, Clarke, Ann E, Wallace, Daniel J, Rahman, Anisur, Merrill, Joan T, Fortin, Paul R, Gladman, Dafna D, Urowitz, Murray B, Petri, Michelle, Ginzler, Ellen M, Dooley, MA, Ramsey-Goldman, Rosalind, Manzi, Susan, Jonsen, Andreas, Alarcón, Graciela S, van Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Lim, S Sam, Inanc, Murat, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Kamen, Diane L, Askanase, Anca, Payne, Katherine, Lunt, Mark, Peek, Niels, Geifman, Nophar, Gavan, Sean, Armitt, Gillian, Doherty, Patrick, Prattley, Jennifer, Azadbakht, Narges, Papazian, Angela, Le Sueur, Helen, Farrelly, Carmen, Richardson, Clare, Shabbir, Zunnaira, Hewitt, Lauren, McHugh, Neil, Reynolds, John, Young, Stephen, Jayne, David, Farewell, Vern, Pickering, Matthew, Lightstone, Elizabeth, Gilmore, Alyssa, Botto, Marina, Vyse, Timothy, Morris, David Lester, D’Cruz, D, Vital, Edward, Wittmann, Miriam, Emery, Paul, Beresford, Michael, Hedrich, Christian, Midgley, Angela, Gritzfeld, Jenna, Ehrenstein, Michael, Parvaz, Mariea, Dunnage, Jane, Batchelor, Jane, Holland, E, and Upsall, Pauline
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Lupus ,Clinical Research ,Humans ,Lupus Erythematosus ,Systemic ,Immunosuppressive Agents ,Outcome Assessment ,Health Care ,Logistic Models ,United Kingdom ,Severity of Illness Index ,International Collaborating Clinics Consortium ,MASTERPLANS Consortium ,Systemic lupus erythematosus ,clinical outcomes ,disease activity ,predictors ,Arthritis & Rheumatology ,Clinical sciences - Abstract
BackgroundWe aimed to identify factors associated with a significant reduction in SLE disease activity over 12 months assessed by the BILAG Index.MethodsIn an international SLE cohort, we studied patients from their 'inception enrolment' visit. We also defined an 'active disease' cohort of patients who had active disease similar to that needed for enrolment into clinical trials. Outcomes at 12 months were; Major Clinical Response (MCR: reduction to classic BILAG C in all domains, steroid dose of ≤7.5 mg and SLEDAI ≤ 4) and 'Improvement' (reduction to ≤1B score in previously active organs; no new BILAG A/B; stable or reduced steroid dose; no increase in SLEDAI). Univariate and multivariate logistic regression with Least Absolute Shrinkage and Selection Operator (LASSO) and cross-validation in randomly split samples were used to build prediction models.Results'Inception enrolment' (n = 1492) and 'active disease' (n = 924) patients were studied. Models for MCR performed well (ROC AUC = .777 and .732 in the inception enrolment and active disease cohorts, respectively). Models for Improvement performed poorly (ROC AUC = .574 in the active disease cohort). MCR in both cohorts was associated with anti-malarial use and inversely associated with active disease at baseline (BILAG or SLEDAI) scores, BILAG haematological A/B scores, higher steroid dose and immunosuppressive use.ConclusionBaseline predictors of response in SLE can help identify patients in clinic who are less likely to respond to standard therapy. They are also important as stratification factors when designing clinical trials in order to better standardize overall usual care response rates.
- Published
- 2023
3. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
- Author
-
Chandran, Vinod, Bessette, Louis, Thorne, Carter, Sheriff, Maqbool, Rahman, Proton, Gladman, Dafna D., Anwar, Sabeen, Jelley, Jennifer, Gaudreau, Anne-Julie, Chohan, Manprit, and Sampalis, John S.
- Published
- 2024
- Full Text
- View/download PDF
4. Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
- Author
-
Curtis, Jeffrey R., McInnes, Iain B., Rahman, Proton, Gladman, Dafna D., Peterson, Steven, Yang, Feifei, Adejoro, Oluwakayode, Kollmeier, Alexa P., Shiff, Natalie J., Han, Chenglong, Shawi, May, Tillett, William, and Mease, Philip J.
- Published
- 2024
- Full Text
- View/download PDF
5. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
- Author
-
Mease, Philip J., Gladman, Dafna D., Poddubnyy, Denis, Chakravarty, Soumya D., Shawi, May, Kollmeier, Alexa P., Xu, Xie L., Xu, Stephen, Deodhar, Atul, and Baraliakos, Xenofon
- Published
- 2023
- Full Text
- View/download PDF
6. Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
- Author
-
Almeida-Brasil, Celline C, Hanly, John G, Urowitz, Murray, Clarke, Ann Elaine, Ruiz-Irastorza, Guillermo, Gordon, Caroline, Ramsey-Goldman, Rosalind, Petri, Michelle A, Ginzler, Ellen M, Wallace, Daniel J, Bae, Sang-Cheol, Romero-Diaz, Juanita, Dooley, Mary-Anne, Peschken, Christine, Isenberg, David, Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, S Sam, van Vollenhoven, Ronald, Nived, Ola, Jönsen, Andreas, Kamen, Diane L, Aranow, Cynthia, Sánchez-Guerrero, Jorge, Gladman, Dafna D, Fortin, Paul R, Alarcon, Graciela S, Merrill, Joan T, Kalunian, Kenneth, Ramos-Casals, Manuel, Steinsson, Kristjan, Zoma, A, Askanase, Anca D, Khamashta, Munther, Bruce, Ian N, Inanc, Murat, Lukusa, Luck, and Bernatsky, Sasha
- Subjects
Biomedical and Clinical Sciences ,Ophthalmology and Optometry ,Aging ,Prevention ,Autoimmune Disease ,Lupus ,Clinical Research ,Eye Disease and Disorders of Vision ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Eye ,Good Health and Well Being ,Humans ,Female ,Aged ,Male ,Hydroxychloroquine ,Antirheumatic Agents ,Lupus Erythematosus ,Systemic ,Retinal Diseases ,Chloroquine ,epidemiology ,lupus erythematosus ,systemic ,outcome assessment ,health care ,lupus erythematosus ,systemic ,outcome assessment ,health care ,Clinical sciences ,Immunology - Abstract
ObjectiveTo evaluate hydroxychloroquine (HCQ)-related retinal toxicity in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.MethodsData were collected at annual study visits between 1999 and 2019. We followed patients with incident SLE from first visit on HCQ (time zero) up to time of retinal toxicity (outcome), death, loss-to-follow-up or end of study. Potential retinal toxicity was identified from SLICC Damage Index scores; cases were confirmed with chart review. Using cumulative HCQ duration as the time axis, we constructed univariate Cox regression models to assess if covariates (ie, HCQ daily dose/kg, sex, race/ethnicity, age at SLE onset, education, body mass index, renal damage, chloroquine use) were associated with HCQ-related retinal toxicity.ResultsWe studied 1460 patients (89% female, 52% white). Retinal toxicity was confirmed in 11 patients (incidence 1.0 per 1000 person-years, 0.8% overall). Average cumulative time on HCQ in those with retinal toxicity was 7.4 (SD 3.2) years; the first case was detected 4 years after HCQ initiation. Risk of retinal toxicity was numerically higher in older patients at SLE diagnosis (univariate HR 1.05, 95% CI 1.01 to 1.09).ConclusionsThis is the first assessment of HCQ and retinal disease in incident SLE. We did not see any cases of retinopathy within the first 4 years of HCQ. Cumulative HCQ may be associated with increased risk. Ophthalmology monitoring (and formal assessment of cases of potential toxicity, by a retinal specialist) remains important, especially in patients on HCQ for 10+ years, those needing higher doses and those of older age at SLE diagnosis.
- Published
- 2022
7. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
- Author
-
Choi, May Yee, Clarke, Ann Elaine, Urowitz, Murray, Hanly, John, St-Pierre, Yvan, Gordon, Caroline, Bae, Sang-Cheol, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J, Isenberg, David, Rahman, Anisur, Merrill, Joan T, Fortin, Paul R, Gladman, Dafna D, Bruce, Ian N, Petri, Michelle, Ginzler, Ellen M, Dooley, Mary Anne, Ramsey-Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela S, van Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Lim, Sam, Inanc, Murat, Kalunian, Ken, Jacobsen, Søren, Peschken, Christine, Kamen, Diane L, Askanase, Anca, Buyon, Jill P, Costenbader, Karen H, and Fritzler, Marvin J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Lupus ,Antibodies ,Antinuclear ,Autoantibodies ,Cross-Sectional Studies ,Fluorescent Antibody Technique ,Indirect ,Humans ,Lupus Erythematosus ,Systemic ,Systemic Lupus Erythematosus ,Autoimmunity ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectivesA perception derived from cross-sectional studies of small systemic lupus erythematosus (SLE) cohorts is that there is a marked discrepancy between antinuclear antibody (ANA) assays, which impacts on clinicians' approach to diagnosis and follow-up. We compared three ANA assays in a longitudinal analysis of a large international incident SLE cohort retested regularly and followed for 5 years.MethodsDemographic, clinical and serological data was from 805 SLE patients at enrolment, year 3 and 5. Two HEp-2 indirect immunofluorescence assays (IFA1, IFA2), an ANA ELISA, and SLE-related autoantibodies were performed in one laboratory. Frequencies of positivity, titres or absorbance units (AU), and IFA patterns were compared using McNemar, Wilcoxon and kappa statistics, respectively.ResultsAt enrolment, ANA positivity (≥1:80) was 96.1% by IFA1 (median titre 1:1280 (IQR 1:640-1:5120)), 98.3% by IFA2 (1:2560 (IQR 1:640-1:5120)) and 96.6% by ELISA (176.3 AU (IQR 106.4 AU-203.5 AU)). At least one ANA assay was positive for 99.6% of patients at enrolment. At year 5, ANA positivity by IFAs (IFA1 95.2%; IFA2 98.9%) remained high, while there was a decrease in ELISA positivity (91.3%, p91% agreement in ANA positivity at all time points and ≥71% agreement in IFA patterns between IFA1 and IFA2.ConclusionIn recent-onset SLE, three ANA assays demonstrated commutability with a high proportion of positivity and titres or AU. However, over 5 years follow-up, there was modest variation in ANA assay performance. In clinical situations where the SLE diagnosis is being considered, a negative test by either the ELISA or HEp-2 IFA may require reflex testing.
- Published
- 2022
8. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
- Author
-
Ogdie, Alexis, Gladman, Dafna D., Coates, Laura C., Pournara, Effie, Parikh, Bhumik, and Mease, Philip J.
- Published
- 2023
- Full Text
- View/download PDF
9. Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index
- Author
-
Legge, Alexandra, Kirkland, Susan, Rockwood, Kenneth, Andreou, Pantelis, Bae, Sang‐Cheol, Gordon, Caroline, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Wallace, Daniel J, Bernatsky, Sasha, Clarke, Ann E, Merrill, Joan T, Ginzler, Ellen M, Fortin, Paul R, Gladman, Dafna D, Urowitz, Murray B, Bruce, Ian N, Isenberg, David A, Rahman, Anisur, Alarcón, Graciela S, Petri, Michelle, Khamashta, Munther A, Dooley, MA, Ramsey‐Goldman, Rosalind, Manzi, Susan, Zoma, Asad A, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Inanc, Murat, Vollenhoven, Ronald F, Jonsen, Andreas, Nived, Ola, Ramos‐Casals, Manuel, Kamen, Diane L, Kalunian, Kenneth C, Jacobsen, Søren, Peschken, Christine A, Askanase, Anca, and Hanly, John G
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Lupus ,Clinical Research ,Autoimmune Disease ,Inflammatory and immune system ,Good Health and Well Being ,Adult ,Female ,Frailty ,Hospitalization ,Humans ,Immunosuppressive Agents ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Severity of Illness Index ,Young Adult ,Clinical Sciences ,Public Health and Health Services ,Psychology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveThe Systemic Lupus International Collaborating Clinics (SLICC) frailty index (FI) predicts mortality and damage accrual in systemic lupus erythematosus (SLE), but its association with hospitalizations has not been described. Our objective was to estimate the association of baseline SLICC-FI values with future hospitalizations in the SLICC inception cohort.MethodsBaseline SLICC-FI scores were calculated. The number and duration of inpatient hospitalizations during follow-up were recorded. Negative binomial regression was used to estimate the association between baseline SLICC-FI values and the rate of hospitalizations per patient-year of follow-up. Linear regression was used to estimate the association of baseline SLICC-FI scores with the proportion of follow-up time spent in the hospital. Multivariable models were adjusted for relevant baseline characteristics.ResultsThe 1,549 patients with SLE eligible for this analysis were mostly female (88.7%), with a mean ± SD age of 35.7 ± 13.3 years and a median disease duration of 1.2 years (interquartile range 0.9-1.5) at baseline. Mean ± SD baseline SLICC-FI was 0.17 ± 0.08. During mean ± SD follow-up of 7.2 ± 3.7 years, 614 patients (39.6%) experienced 1,570 hospitalizations. Higher baseline SLICC-FI values (per 0.05 increment) were associated with more frequent hospitalizations during follow-up, with an incidence rate ratio of 1.21 (95% confidence interval [95% CI] 1.13-1.30) after adjustment for baseline age, sex, glucocorticoid use, immunosuppressive use, ethnicity/location, SLE Disease Activity Index 2000 score, SLICC/American College of Rheumatology Damage Index score, and disease duration. Among patients with ≥1 hospitalization, higher baseline SLICC-FI values predicted a greater proportion of follow-up time spent hospitalized (relative rate 1.09 [95% CI 1.02-1.16]).ConclusionThe SLICC-FI predicts future hospitalizations among incident SLE patients, further supporting the SLICC-FI as a valid health measure in SLE.
- Published
- 2022
10. Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
- Author
-
Calabrese, Cassandra, Desai, Seemal R., Duffin, Kristina C., Feldman, Steven R., Gladman, Dafna D., Glick, Brad P., Han, George, Harris, Jason, Hawkes, Jason E., Hsu, Sylvia, Huang, Margaret Y., Kalb, Robert E., Kircik, Leon H., Koo, John, Lewitt, G. Michael, Liao, Wilson J., Liu, Clive, Merola, Joseph F., Prussick, Ronald B., Reddy, Soumya M., Schwartzman, Sergio, Smith, Jessica N., Soung, Jennifer, Van Voorhees, Abby S., Wallace, Elizabeth B., Weinberg, Jeffrey M., Lee, Lara Wine, Yamauchi, Paul S., Armstrong, April W., Elston, Carly A., Elewski, Boni E., Ferris, Laura K., Gottlieb, Alice B., and Lebwohl, Mark G.
- Published
- 2024
- Full Text
- View/download PDF
11. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
- Author
-
Almeida-Brasil, Celline C, Hanly, John G, Urowitz, Murray, Clarke, Ann Elaine, Ruiz-Irastorza, Guillermo, Gordon, Caroline, Ramsey-Goldman, Rosalind, Petri, Michelle, Ginzler, Ellen M, Wallace, DJ, Bae, Sang-Cheol, Romero-Diaz, Juanita, Dooley, Mary Anne, Peschken, Christine, Isenberg, David, Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, Sam, van Vollenhoven, Ronald F, Nived, Ola, Jönsen, Andreas, Kamen, Diane L, Aranow, Cynthia, Sanchez-Guerrero, Jorge, Gladman, Dafna D, Fortin, Paul R, Alarcón, Graciela S, Merrill, Joan T, Kalunian, Kenneth, Ramos-Casals, Manuel, Steinsson, Kristján, Zoma, Asad, Askanase, Anca, Khamashta, Munther A, Bruce, Ian N, Inanc, Murat, Abrahamowicz, Michal, and Bernatsky, Sasha
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lupus ,Autoimmune Disease ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Antirheumatic Agents ,Drug Tapering ,Female ,Follow-Up Studies ,Humans ,Hydroxychloroquine ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Prospective Studies ,Symptom Flare Up ,Treatment Outcome ,autoimmune diseases ,epidemiology ,hydroxychloroquine ,systemic lupus erythematosus ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectivesTo evaluate systemic lupus erythematosus (SLE) flares following hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance.MethodsWe analysed prospective data from the Systemic Lupus International Collaborating Clinics (SLICC) cohort, enrolled from 33 sites within 15 months of SLE diagnosis and followed annually (1999-2019). We evaluated person-time contributed while on the initial HCQ dose ('maintenance'), comparing this with person-time contributed after a first dose reduction, and after a first HCQ discontinuation. We estimated time to first flare, defined as either subsequent need for therapy augmentation, increase of ≥4 points in the SLE Disease Activity Index-2000, or hospitalisation for SLE. We estimated adjusted HRs (aHRs) with 95% CIs associated with reducing/discontinuing HCQ (vs maintenance). We also conducted separate multivariable hazard regressions in each HCQ subcohort to identify factors associated with flare.ResultsWe studied 1460 (90% female) patients initiating HCQ. aHRs for first SLE flare were 1.20 (95% CI 1.04 to 1.38) and 1.56 (95% CI 1.31 to 1.86) for the HCQ reduction and discontinuation groups, respectively, versus HCQ maintenance. Patients with low educational level were at particular risk of flaring after HCQ discontinuation (aHR 1.43, 95% CI 1.09 to 1.87). Prednisone use at time-zero was associated with over 1.5-fold increase in flare risk in all HCQ subcohorts.ConclusionsSLE flare risk was higher after HCQ taper/discontinuation versus HCQ maintenance. Decisions to maintain, reduce or stop HCQ may affect specific subgroups differently, including those on prednisone and/or with low education. Further study of special groups (eg, seniors) may be helpful.
- Published
- 2022
12. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data
- Author
-
Clowse, Megan EB, Eudy, Amanda M, Balevic, Stephen, Sanders-Schmidler, Gillian, Kosinski, Andrzej, Fischer-Betz, Rebecca, Gladman, Dafna D, Molad, Yair, Nalli, Cecilia, Mokbel, Abir, Tincani, Angela, Urowitz, Murray, Bay, Caroline, van Noord, Megan, and Petri, Michelle
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Perinatal Period - Conditions Originating in Perinatal Period ,Pediatric ,Preterm ,Low Birth Weight and Health of the Newborn ,Autoimmune Disease ,Lupus ,Clinical Research ,Infant Mortality ,Contraception/Reproduction ,Reproductive health and childbirth ,Good Health and Well Being ,Antirheumatic Agents ,Female ,Humans ,Hydroxychloroquine ,Infant ,Newborn ,Lupus Erythematosus ,Systemic ,Pregnancy ,Pregnancy Complications ,Pregnancy Outcome ,Lupus Erythematosus ,Systemic ,Health services research ,Epidemiology ,Clinical sciences ,Immunology - Abstract
ObjectiveMultiple guidelines recommend continuing hydroxychloroquine (HCQ) for SLE during pregnancy based on observational data. The goal of this individual patient data meta-analysis was to identify the potential benefits and harms of HCQ use within lupus pregnancies.MethodsEligible studies included prospectively collected pregnancies in women with lupus. After a systematic literature search, seven datasets meeting inclusion criteria were obtained. Pregnancy outcomes and lupus activity were compared for pregnancies with a visit in the first trimester in women who did or did not take HCQ throughout pregnancy. Birth defects were not systematically collected. This analysis was conducted in each dataset, and results were aggregated to provide a pooled OR.ResultsSeven cohorts provided 938 pregnancies in 804 women. After selecting one pregnancy per patient with a first trimester visit, 668 pregnancies were included; 63% took HCQ throughout pregnancy. Compared with pregnancies without HCQ, those with HCQ had lower odds of highly active lupus, but did not have different odds of fetal loss, preterm delivery or pre-eclampsia. Among women with low lupus activity, HCQ reduced the odds of preterm delivery.ConclusionsThis large study of prospectively-collected lupus pregnancies demonstrates a decrease in lupus activity among woman who continue HCQ through pregnancy and no harm to pregnancy outcomes. Like all studies of HCQ in lupus pregnancy, this study is confounded by indication and non-adherence. As this study confirms the safety of HCQ and diminished SLE activity with use, it is consistent with current recommendations to continue HCQ throughout pregnancy.
- Published
- 2022
13. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies
- Author
-
Ugarte-Gil, Manuel Francisco, Mak, Anselm, Leong, Joanna, Dharmadhikari, Bhushan, Kow, Nien Yee, Reátegui-Sokolova, Cristina, Elera-Fitzcarrald, Claudia, Aranow, Cinthia, Arnaud, Laurent, Askanase, Anca D, Bae, Sang-Cheol, Bernatsky, Sasha, Bruce, Ian N, Buyon, Jill, Costedoat-Chalumeau, Nathalie, Dooley, Mary Ann, Fortin, Paul R, Ginzler, Ellen M, Gladman, Dafna D, Hanly, John, Inanc, Murat, Isenberg, David, Jacobsen, Soren, James, Judith A, Jönsen, Andreas, Kalunian, Kenneth, Kamen, Diane L, Lim, Sung Sam, Morand, Eric, Mosca, Marta, Peschken, Christine, Pons-Estel, Bernardo A, Rahman, Anisur, Ramsey-Goldman, Rosalind, Reynolds, John, Romero-Diaz, Juanita, Ruiz-Irastorza, Guillermo, Sánchez-Guerrero, Jorge, Svenungsson, Elisabet, Urowitz, Murray, Vinet, Evelyne, van Vollenhoven, Ronald F, Voskuyl, Alexandre, Wallace, Daniel J, Petri, Michelle A, Manzi, Susan, Clarke, Ann Elaine, Cheung, Mike, Farewell, Vernon, and Alarcon, Graciela S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Lupus ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Female ,Glucocorticoids ,Humans ,Incidence ,Longitudinal Studies ,Lupus Erythematosus ,Systemic ,Observational Studies as Topic ,Regression Analysis ,glucocorticoids ,outcome assessment ,health care ,lupus erythematosus ,systemic ,Clinical sciences ,Immunology - Abstract
In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC) exposure are known to contribute to irreversible organ damage. We aimed to examine the association between GC exposure and organ damage occurrence. We conducted a literature search (PubMed (Medline), Embase and Cochrane January 1966-October 2021). We identified original longitudinal observational studies reporting GC exposure as the proportion of users and/or GC use with dose information as well as the occurrence of new major organ damage as defined in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Meta-regression analyses were performed. Reviews, case-reports and studies with
- Published
- 2021
14. Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort
- Author
-
Hanly, John G, Gordon, Caroline, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Bernatsky, Sasha, Clarke, Ann E, Wallace, Daniel J, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Fortin, Paul R, Gladman, Dafna D, Urowitz, Murray B, Bruce, Ian N, Petri, Michelle, Ginzler, Ellen M, Dooley, MA, Ramsey‐Goldman, Rosalind, Manzi, Susan, Jonsen, Andreas, Alarcón, Graciela S, Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Inanc, Murat, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Kamen, Diane L, Askanase, Anca, and Farewell, Vernon
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Clinical Research ,Lupus ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Adult ,Female ,Headache ,Humans ,Longitudinal Studies ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Models ,Theoretical ,Prospective Studies ,Quality of Life ,Sex Factors ,Young Adult ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo determine predictors of change in neuropsychiatric (NP) event status in a large, prospective, international inception cohort of patients with systemic lupus erythematosus (SLE).MethodsUpon enrollment and annually thereafter, NP events attributed to SLE and non-SLE causes and physician-determined resolution were documented. Factors potentially associated with the onset and resolution of NP events were determined by time-to-event analysis using a multistate modeling structure.ResultsNP events occurred in 955 (52.3%) of 1,827 patients, and 593 (31.0%) of 1,910 unique events were attributed to SLE. For SLE-associated NP (SLE NP) events, multivariate analysis revealed a positive association with male sex (P = 0.028), concurrent non-SLE NP events excluding headache (P < 0.001), active SLE (P = 0.012), and glucocorticoid use (P = 0.008). There was a negative association with Asian race (P = 0.002), postsecondary education (P = 0.001), and treatment with immunosuppressive drugs (P = 0.019) or antimalarial drugs (P = 0.056). For non-SLE NP events excluding headache, there was a positive association with concurrent SLE NP events (P < 0.001) and a negative association with African race (P = 0.012) and Asian race (P < 0.001). NP events attributed to SLE had a higher resolution rate than non-SLE NP events, with the exception of headache, which had comparable resolution rates. For SLE NP events, multivariate analysis revealed that resolution was more common in patients of Asian race (P = 0.006) and for central/focal NP events (P < 0.001). For non-SLE NP events, resolution was more common in patients of African race (P = 0.017) and less common in patients who were older at SLE diagnosis (P < 0.001).ConclusionIn a large and long-term study of the occurrence and resolution of NP events in SLE, we identified subgroups with better and worse prognosis. The course of NP events differs greatly depending on their nature and attribution.
- Published
- 2021
15. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications
- Author
-
Bernatsky, Sasha, Ramsey‐Goldman, Rosalind, Urowitz, Murray B, Hanly, John G, Gordon, Caroline, Petri, Michelle A, Ginzler, Ellen M, Wallace, Daniel J, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Dooley, Mary Anne, Peschken, Christine A, Isenberg, David A, Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, S Sam, Vollenhoven, Ronald, Nived, Ola, Kamen, Diane L, Aranow, Cynthia, Ruiz‐Irastorza, Guillermo, Sánchez‐Guerrero, Jorge, Gladman, Dafna D, Fortin, Paul R, Alarcón, Graciela S, Merrill, Joan T, Kalunian, Kenneth C, Ramos‐Casals, Manuel, Steinsson, Kristjan, Zoma, Asad, Askanase, Anca, Khamashta, Munther A, Bruce, Ian, Inanc, Murat, and Clarke, Ann E
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Autoimmune Disease ,Prevention ,Lung ,Patient Safety ,Lung Cancer ,Lupus ,Rare Diseases ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adult ,Antimalarials ,Female ,Humans ,Immunosuppressive Agents ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Neoplasms ,Risk Factors ,Smoking ,Clinical Sciences ,Public Health and Health Services ,Psychology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveTo assess cancer risk factors in incident systemic lupus erythematosus (SLE).MethodsClinical variables and cancer outcomes were assessed annually among incident SLE patients. Multivariate hazard regression models (overall risk and most common cancers) included demographic characteristics and time-dependent medications (corticosteroids, antimalarial drugs, immunosuppressants), smoking, and the adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000 score.ResultsAmong 1,668 patients (average 9 years follow-up), 65 cancers occurred: 15 breast, 10 nonmelanoma skin, 7 lung, 6 hematologic, 6 prostate, 5 melanoma, 3 cervical, 3 renal, 2 each gastric, head and neck, and thyroid, and 1 each rectal, sarcoma, thymoma, and uterine cancers. Half of the cancers (including all lung cancers) occurred in past/current smokers, versus one-third of patients without cancer. Multivariate analyses indicated that overall cancer risk was related primarily to male sex and older age at SLE diagnosis. In addition, smoking was associated with lung cancer. For breast cancer risk, age was positively associated and antimalarial drugs were negatively associated. Antimalarial drugs and higher disease activity were also negatively associated with nonmelanoma skin cancer risk, whereas age and cyclophosphamide were positively associated. Disease activity was associated positively with hematologic and negatively with nonmelanoma skin cancer risk.ConclusionSmoking is a key modifiable risk factor, especially for lung cancer, in SLE. Immunosuppressive medications were not clearly associated with higher risk except for cyclophosphamide and nonmelanoma skin cancer. Antimalarials were negatively associated with breast cancer and nonmelanoma skin cancer risk. SLE activity was associated positively with hematologic cancer and negatively with nonmelanoma skin cancer. Since the absolute number of cancers was small, additional follow-up will help consolidate these findings.
- Published
- 2021
16. Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort.
- Author
-
Chew, Christine, Reynolds, John A, Lertratanakul, Apinya, Wu, Peggy, Urowitz, Murray, Gladman, Dafna D, Fortin, Paul R, Bae, Sang-Cheol, Gordon, Caroline, Clarke, Ann E, Bernatsky, Sasha, Hanly, John G, Isenberg, David, Rahman, Anisur, Sanchez-Guerrero, Jorge, Romero-Diaz, Juanita, Merrill, Joan, Wallace, Daniel, Ginzler, Ellen, Khamashta, Munther, Nived, Ola, Jönsen, Andreas, Steinsson, Kristjan, Manzi, Susan, Kalunian, Ken, Dooley, Mary Anne, Petri, Michelle, Aranow, Cynthia, van Vollenhoven, Ronald, Stoll, Thomas, Alarcón, Graciela S, Lim, S Sam, Ruiz-Irastorza, Guillermo, Peschken, Christine A, Askanase, Anca D, Kamen, Diane L, İnanç, Murat, Ramsey-Goldman, Rosalind, and Bruce, Ian N
- Subjects
Cardiovascular ,Diabetes ,Clinical Research ,Autoimmune Disease ,Lupus ,Nutrition ,Metabolic and endocrine ,Adult ,Cohort Studies ,Cross-Sectional Studies ,Female ,Global Health ,Humans ,Insulin Resistance ,Lupus Erythematosus ,Systemic ,Male ,Metabolic Syndrome ,Vitamin D ,Vitamin D Deficiency ,Young Adult ,systemic lupus erythematosus ,vitamin D ,cardiovascular disease ,epidemiology ,Clinical Sciences ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology - Abstract
ObjectivesVitamin D (25(OH)D) deficiency and metabolic syndrome (MetS) may both contribute to increased cardiovascular risk in SLE. We aimed to examine the association of demographic factors, SLE phenotype, therapy and vitamin D levels with MetS and insulin resistance.MethodsThe Systemic Lupus International Collaborating Clinics (SLICC) enrolled patients recently diagnosed with SLE (
- Published
- 2021
17. Persistence of Biologics in the Treatment of Psoriatic Arthritis: Data From a Large Hospital‐Based Longitudinal Cohort
- Author
-
Rida, Mohamad‐Ali, Lee, Ker‐Ai, Chandran, Vinod, Cook, Richard J., and Gladman, Dafna D.
- Published
- 2023
- Full Text
- View/download PDF
18. Investigation into the wait time for consultation in the psoriatic arthritis program
- Author
-
Park, Seiwon, Silverberg, Orli M., Moez, Elham, Chandran, Vinod, and Gladman, Dafna D.
- Published
- 2022
- Full Text
- View/download PDF
19. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
- Author
-
Curtis, Jeffrey R., McInnes, Iain B., Rahman, Proton, Gladman, Dafna D., Peterson, Steven, Agarwal, Prasheen, Yang, Feifei, Kollmeier, Alexa P., Hsia, Elizabeth C., Shiff, Natalie J., Zhou, Bei, Han, Chenglong, Shawi, May, Tillett, William, and Mease, Philip J.
- Published
- 2022
- Full Text
- View/download PDF
20. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
- Author
-
Curtis, Jeffrey R., McInnes, Iain B., Rahman, Proton, Gladman, Dafna D., Yang, Feifei, Peterson, Steven, Agarwal, Prasheen, Kollmeier, Alexa P., Hsia, Elizabeth C., Han, Chenglong, Shiff, Natalie J., Shawi, May, Tillett, William, and Mease, Philip J.
- Published
- 2022
- Full Text
- View/download PDF
21. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index
- Author
-
Legge, Alexandra, Kirkland, Susan, Rockwood, Kenneth, Andreou, Pantelis, Bae, Sang‐Cheol, Gordon, Caroline, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Wallace, Daniel J, Bernatsky, Sasha, Clarke, Ann E, Merrill, Joan T, Ginzler, Ellen M, Fortin, Paul R, Gladman, Dafna D, Urowitz, Murray B, Bruce, Ian N, Isenberg, David A, Rahman, Anisur, Alarcón, Graciela S, Petri, Michelle, Khamashta, Munther A, Dooley, MA, Ramsey‐Goldman, Rosalind, Manzi, Susan, Zoma, Asad A, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Inanc, Murat, Vollenhoven, Ronald F, Jonsen, Andreas, Nived, Ola, Ramos‐Casals, Manuel, Kamen, Diane L, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Askanase, Anca, and Hanly, John G
- Subjects
Autoimmune Disease ,Lupus ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Inflammatory and immune system ,Good Health and Well Being ,Adult ,Disease Progression ,Female ,Frailty ,Humans ,Immunosuppressive Agents ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Quality of Life ,Severity of Illness Index ,Young Adult ,Clinical Sciences ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology - Abstract
ObjectiveThe Systemic Lupus International Collaborating Clinics (SLICC) frailty index (FI) has been shown to predict mortality, but its association with other important outcomes is unknown. We examined the association of baseline SLICC FI values with damage accrual in the SLICC inception cohort.MethodsThe baseline visit was defined as the first visit at which both organ damage (SLICC/American College of Rheumatology Damage Index [SDI]) and health-related quality of life (Short Form 36) were assessed. Baseline SLICC FI scores were calculated. Damage accrual was measured by the increase in SDI between the baseline assessment and the last study visit. Multivariable negative binomial regression was used to estimate the association between baseline SLICC FI values and the rate of increase in the SDI during follow-up, adjusting for relevant demographic and clinical characteristics.ResultsThe 1,549 systemic lupus erythematosus (SLE) patients eligible for this analysis were mostly female (88.7%) with a mean ± SD age of 35.7 ± 13.3 years and a median disease duration of 1.2 years (interquartile range 0.9-1.5 years) at baseline. The mean ± SD baseline SLICC FI was 0.17 ± 0.08. Over a mean ± SD follow-up of 7.2 ± 3.7 years, 653 patients (42.2%) had an increase in SDI. Higher baseline SLICC FI values (per 0.05 increase) were associated with higher rates of increase in the SDI during follow-up (incidence rate ratio [IRR] 1.19 [95% confidence interval 1.13-1.25]), after adjusting for age, sex, ethnicity/region, education, baseline SLE Disease Activity Index 2000, baseline SDI, and baseline use of glucocorticoids, antimalarials, and immunosuppressive agents.ConclusionOur findings indicate that the SLICC FI predicts damage accrual in incident SLE, which further supports the SLICC FI as a valid health measure in SLE.
- Published
- 2020
22. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
- Author
-
Hanly, John G, Li, Qiuju, Su, Li, Urowitz, Murray B, Gordon, Caroline, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Bernatsky, Sasha, Clarke, Ann E, Wallace, Daniel J, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Fortin, Paul R, Gladman, Dafna D, Bruce, Ian N, Petri, Michelle, Ginzler, Ellen M, Dooley, MA, Steinsson, Kristjan, Ramsey‐Goldman, Rosalind, Zoma, Asad A, Manzi, Susan, Nived, Ola, Jonsen, Andreas, Khamashta, Munther A, Alarcón, Graciela S, Svenungsson, Elisabet, Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Ramos‐Casals, Manuel, Lim, S Sam, Inanc, Murat, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Kamen, Diane L, Askanase, Anca, Theriault, Chris, and Farewell, Vernon
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Chronic Pain ,Neurosciences ,Pain Research ,Clinical Research ,Neurodegenerative ,Lupus ,Peripheral Neuropathy ,Autoimmune Disease ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Neurological ,Good Health and Well Being ,Adult ,Age Factors ,Cohort Studies ,Cranial Nerve Diseases ,Female ,Humans ,Lupus Erythematosus ,Systemic ,Lupus Vasculitis ,Central Nervous System ,Male ,Middle Aged ,Mononeuropathies ,Multivariate Analysis ,Peripheral Nervous System Diseases ,Proportional Hazards Models ,Severity of Illness Index ,Young Adult ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo determine the frequency, clinical characteristics, associations, and outcomes of different types of peripheral nervous system (PNS) disease in a multiethnic/multiracial, prospective inception cohort of systemic lupus erythematosus (SLE) patients.MethodsPatients were evaluated annually for 19 neuropsychiatric (NP) events including 7 types of PNS disease. SLE disease activity, organ damage, autoantibodies, and patient and physician assessment of outcome were measured. Time to event and linear regressions were used as appropriate.ResultsOf 1,827 SLE patients, 88.8% were female, and 48.8% were white. The mean ± SD age was 35.1 ± 13.3 years, disease duration at enrollment was 5.6 ± 4.2 months, and follow-up was 7.6 ± 4.6 years. There were 161 PNS events in 139 (7.6%) of 1,827 patients. The predominant events were peripheral neuropathy (66 of 161 [41.0%]), mononeuropathy (44 of 161 [27.3%]), and cranial neuropathy (39 of 161 [24.2%]), and the majority were attributed to SLE. Multivariate Cox regressions suggested longer time to resolution in patients with a history of neuropathy, older age at SLE diagnosis, higher SLE Disease Activity Index 2000 scores, and for peripheral neuropathy versus other neuropathies. Neuropathy was associated with significantly lower Short Form 36 (SF-36) physical and mental component summary scores versus no NP events. According to physician assessment, the majority of neuropathies resolved or improved over time, which was associated with improvements in SF-36 summary scores for peripheral neuropathy and mononeuropathy.ConclusionPNS disease is an important component of total NPSLE and has a significant negative impact on health-related quality of life. The outcome is favorable for most patients, but our findings indicate that several factors are associated with longer time to resolution.
- Published
- 2020
23. Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus
- Author
-
Legge, Alexandra, Kirkland, Susan, Rockwood, Kenneth, Andreou, Pantelis, Bae, Sang-Cheol, Gordon, Caroline, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Wallace, Daniel J, Bernatsky, Sasha, Clarke, Ann E, Merrill, Joan T, Ginzler, Ellen M, Fortin, Paul, Gladman, Dafna D, Urowitz, Murray B, Bruce, Ian N, Isenberg, David A, Rahman, Anisur, Alarcón, Graciela S, Petri, Michelle, Khamashta, Munther A, Dooley, MA, Ramsey-Goldman, Rosalind, Manzi, Susan, Zoma, Asad A, Aranow, Cynthia, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Lim, S Sam, Inanc, Murat, van Vollenhoven, Ronald F, Jonsen, Andreas, Nived, Ola, Ramos-Casals, Manuel, Kamen, Diane L, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Askanase, Anca, and Hanly, John G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Autoimmune Disease ,Lupus ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Adult ,Female ,Frailty ,Humans ,Longitudinal Studies ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Patient Outcome Assessment ,Prevalence ,Severity of Illness Index ,Young Adult ,SYSTEMIC LUPUS ERYTHEMATOSUS ,OUTCOME ASSESSMENT ,COHORT STUDIES ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo construct a Frailty Index (FI) as a measure of vulnerability to adverse outcomes among patients with systemic lupus erythematosus (SLE), using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.MethodsThe SLICC inception cohort consists of recently diagnosed patients with SLE followed annually with clinical and laboratory assessments. For this analysis, the baseline visit was defined as the first study visit at which sufficient information was available for construction of an FI. Following a standard procedure, variables from the SLICC database were evaluated as potential health deficits. Selected health deficits were then used to generate a SLICC-FI. The prevalence of frailty in the baseline dataset was evaluated using established cutpoints for FI values.ResultsThe 1683 patients with SLE (92.1% of the overall cohort) eligible for inclusion in the baseline dataset were mostly female (89%) with mean (SD) age 35.7 (13.4) years and mean (SD) disease duration 18.8 (15.7) months at baseline. Of 222 variables, 48 met criteria for inclusion in the SLICC-FI. Mean (SD) SLICC-FI was 0.17 (0.08) with a range from 0 to 0.51. At baseline, 27.1% (95% CI 25.0-29.2) of patients were classified as frail, based on SLICC-FI values > 0.21.ConclusionThe SLICC inception cohort permits feasible construction of an FI for use in patients with SLE. Even in a relatively young cohort of patients with SLE, frailty was common. The SLICC-FI may be a useful tool for identifying patients with SLE who are most vulnerable to adverse outcomes, but validation of this index is required prior to its use.
- Published
- 2020
24. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
- Author
-
Merola, Joseph F, Landewé, Robert, McInnes, Iain B, Mease, Philip J, Ritchlin, Christopher T, Tanaka, Yoshiya, Asahina, Akihiko, Behrens, Frank, Gladman, Dafna D, Gossec, Laure, Gottlieb, Alice B, Thaçi, Diamant, Warren, Richard B, Ink, Barbara, Assudani, Deepak, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, and Coates, Laura C
- Published
- 2023
- Full Text
- View/download PDF
25. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
- Author
-
Coates, Laura C., Soriano, Enrique R., Corp, Nadia, Bertheussen, Heidi, Callis Duffin, Kristina, Campanholo, Cristiano B., Chau, Jeffrey, Eder, Lihi, Fernández-Ávila, Daniel G., FitzGerald, Oliver, Garg, Amit, Gladman, Dafna D., Goel, Niti, Helliwell, Philip S., Husni, M. Elaine, Jadon, Deepak R., Katz, Arnon, Laheru, Dhruvkumar, Latella, John, Leung, Ying-Ying, Lindsay, Christine, Lubrano, Ennio, Mazzuoccolo, Luis Daniel, Mease, Philip J., O’Sullivan, Denis, Ogdie, Alexis, Olsder, Wendy, Palominos, Penelope Esther, Schick, Lori, Steinkoenig, Ingrid, de Wit, Maarten, van der Windt, D. A., and Kavanaugh, Arthur
- Published
- 2022
- Full Text
- View/download PDF
26. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling
- Author
-
Clarke, Ann E., Hanly, John G., Urowitz, Murray B., St. Pierre, Yvan, Gordon, Caroline, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J., Isenberg, David A., Rahman, Anisur, Merrill, Joan T., Fortin, Paul R., Gladman, Dafna D., Bruce, Ian N., Petri, Michelle, Ginzler, Ellen M., Dooley, Mary Anne, Ramsey‐Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela S., Van Vollenhoven, Ronald F., Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S. Sam, Inanc, Murat, Kalunian, Kenneth C., Jacobsen, Soren, Peschken, Christine A., Kamen, Diane L., Askanase, Anca, and Farewell, Vernon
- Published
- 2023
- Full Text
- View/download PDF
27. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses
- Author
-
FitzGerald, Oliver, primary, Gladman, Dafna D., additional, Mease, Philip J., additional, Ritchlin, Christopher, additional, Smolen, Josef S., additional, Gao, Lu, additional, Hu, Yanhua, additional, Nowak, Miroslawa, additional, Banerjee, Subhashis, additional, and Catlett, Ian, additional
- Published
- 2024
- Full Text
- View/download PDF
28. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies
- Author
-
Baraliakos, Xenofon, primary, Gladman, Dafna D, additional, Chakravarty, Soumya D, additional, Gong, Cinty, additional, Shawi, May, additional, Rampakakis, Emmanouil, additional, Kishimoto, Mitsumasa, additional, Soriano, Enrique R, additional, and Mease, Philip J, additional
- Published
- 2024
- Full Text
- View/download PDF
29. Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus
- Author
-
Krustev, Eugene, primary, Hanly, John G, additional, Chin, Ricky, additional, Buhler, Katherine A, additional, Urowitz, Murray B, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sánchez-Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Wallace, Daniel J, additional, Isenberg, David, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle A, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S, additional, van Vollenhoven, Ronald F, additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Lim, Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth C, additional, Jacobsen, Søren, additional, Peschken, Christine A, additional, Kamen, Diane L, additional, Askenase, Anca, additional, Buyon, Jill, additional, Fritzler, Marvin J, additional, Clarke, Ann E, additional, and Choi, May Y, additional
- Published
- 2024
- Full Text
- View/download PDF
30. Exploring cannabis use and perspectives among psoriatic disease patients
- Author
-
Tsang, Jackie, Silverberg, Orli, Machhar, Rohan, Pollock, Remy, Pereira, Daniel, Sutton, Mitchell, Gladman, Dafna D., and Rosen, Cheryl F.
- Published
- 2022
- Full Text
- View/download PDF
31. Cardiac Magnetic Resonance Imaging and Clinical Follow-up in Antimalarial-induced Cardiomyopathy in Patients With Systemic Lupus Erythematosus
- Author
-
Shalmon, Tamar, Thavendiranathan, Paaladinesh, Harvey, Paula, Akhtari, Shadi, Tselios, Kostantinos, Gladman, Dafna D., and Hanneman, Kate
- Published
- 2023
- Full Text
- View/download PDF
32. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
- Author
-
Aringer, Martin, Costenbader, Karen, Daikh, David, Brinks, Ralph, Mosca, Marta, Ramsey‐Goldman, Rosalind, Smolen, Josef S, Wofsy, David, Boumpas, Dimitrios T, Kamen, Diane L, Jayne, David, Cervera, Ricard, Costedoat‐Chalumeau, Nathalie, Diamond, Betty, Gladman, Dafna D, Hahn, Bevra, Hiepe, Falk, Jacobsen, Søren, Khanna, Dinesh, Lerstrøm, Kirsten, Massarotti, Elena, McCune, Joseph, Ruiz‐Irastorza, Guillermo, Sanchez‐Guerrero, Jorge, Schneider, Matthias, Urowitz, Murray, Bertsias, George, Hoyer, Bimba F, Leuchten, Nicolai, Tani, Chiara, Tedeschi, Sara K, Touma, Zahi, Schmajuk, Gabriela, Anic, Branimir, Assan, Florence, Chan, Tak Mao, Clarke, Ann Elaine, Crow, Mary K, Czirják, László, Doria, Andrea, Graninger, Winfried, Halda‐Kiss, Bernadett, Hasni, Sarfaraz, Izmirly, Peter M, Jung, Michelle, Kumánovics, Gábor, Mariette, Xavier, Padjen, Ivan, Pego‐Reigosa, José M, Romero‐Diaz, Juanita, Fernández, Íñigo Rúa‐Figueroa, Seror, Raphaèle, Stummvoll, Georg H, Tanaka, Yoshiya, Tektonidou, Maria G, Vasconcelos, Carlos, Vital, Edward M, Wallace, Daniel J, Yavuz, Sule, Meroni, Pier Luigi, Fritzler, Marvin J, Naden, Ray, Dörner, Thomas, and Johnson, Sindhu R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lupus ,Autoimmune Disease ,Inflammatory and immune system ,Adult ,Antibodies ,Antinuclear ,Antibodies ,Antiphospholipid ,Autoantibodies ,Cohort Studies ,Complement System Proteins ,Decision Support Techniques ,Delphi Technique ,Europe ,Female ,Humans ,International Cooperation ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Rheumatology ,Sensitivity and Specificity ,Societies ,Medical ,United States ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).MethodsThis international initiative had four phases. 1) Evaluation of antinuclear antibody (ANA) as an entry criterion through systematic review and meta-regression of the literature and criteria generation through an international Delphi exercise, an early patient cohort, and a patient survey. 2) Criteria reduction by Delphi and nominal group technique exercises. 3) Criteria definition and weighting based on criterion performance and on results of a multi-criteria decision analysis. 4) Refinement of weights and threshold scores in a new derivation cohort of 1,001 subjects and validation compared with previous criteria in a new validation cohort of 1,270 subjects.ResultsThe 2019 EULAR/ACR classification criteria for SLE include positive ANA at least once as obligatory entry criterion; followed by additive weighted criteria grouped in 7 clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and 3 immunologic (antiphospholipid antibodies, complement proteins, SLE-specific antibodies) domains, and weighted from 2 to 10. Patients accumulating ≥10 points are classified. In the validation cohort, the new criteria had a sensitivity of 96.1% and specificity of 93.4%, compared with 82.8% sensitivity and 93.4% specificity of the ACR 1997 and 96.7% sensitivity and 83.7% specificity of the Systemic Lupus International Collaborating Clinics 2012 criteria.ConclusionThese new classification criteria were developed using rigorous methodology with multidisciplinary and international input, and have excellent sensitivity and specificity. Use of ANA entry criterion, hierarchically clustered, and weighted criteria reflects current thinking about SLE and provides an improved foundation for SLE research.
- Published
- 2019
33. Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus
- Author
-
Legge, Alexandra, Kirkland, Susan, Rockwood, Kenneth, Andreou, Pantelis, Bae, Sang‐Cheol, Gordon, Caroline, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Wallace, Daniel J, Bernatsky, Sasha, Clarke, Ann E, Merrill, Joan T, Ginzler, Ellen M, Fortin, Paul, Gladman, Dafna D, Urowitz, Murray B, Bruce, Ian N, Isenberg, David A, Rahman, Anisur, Alarcón, Graciela S, Petri, Michelle, Khamashta, Munther A, Dooley, MA, Ramsey‐Goldman, Rosalind, Manzi, Susan, Steinsson, Kristjan, Zoma, Asad A, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Inanc, Murat, Vollenhoven, Ronald F, Jonsen, Andreas, Nived, Ola, Ramos‐Casals, Manuel, Kamen, Diane L, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Askanase, Anca, and Hanly, John G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,Autoimmune Disease ,Behavioral and Social Science ,Lupus ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Good Health and Well Being ,Adult ,Aged ,Female ,Frailty ,Humans ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Proportional Hazards Models ,Quality of Life ,Reproducibility of Results ,Risk Assessment ,Risk Factors ,Severity of Illness Index ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo evaluate the properties of a frailty index (FI), constructed using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, as a novel health measure in systemic lupus erythematosus (SLE).MethodsFor this secondary analysis, the baseline visit was defined as the first study visit at which both organ damage (SLICC/American College of Rheumatology Damage Index [SDI]) and health-related quality of life (Short-Form 36 [SF-36] scores) were assessed. The SLICC-FI was constructed using baseline data. The SLICC-FI comprises 48 health deficits, including items related to organ damage, disease activity, comorbidities, and functional status. Content, construct, and criterion validity of the SLICC-FI were assessed. Multivariable Cox regression was used to estimate the association between baseline SLICC-FI values and mortality risk, adjusting for demographic and clinical factors.ResultsIn the baseline data set of 1,683 patients with SLE, 89% were female, the mean ± SD age was 35.7 ± 13.4 years, and the mean ± SD disease duration was 18.8 ± 15.7 months. At baseline, the mean ± SD SLICC-FI score was 0.17 ± 0.08 (range 0-0.51). Baseline SLICC-FI values exhibited the expected measurement properties and were weakly correlated with baseline SDI scores (r = 0.26, P < 0.0001). Higher baseline SLICC-FI values (per 0.05 increment) were associated with increased mortality risk (hazard ratio 1.59, 95% confidence interval 1.35-1.87), after adjusting for age, sex, steroid use, ethnicity/region, and baseline SDI scores.ConclusionThe SLICC-FI demonstrates internal validity as a health measure in SLE and might be used to predict future mortality risk. The SLICC-FI is potentially valuable for quantifying vulnerability among patients with SLE, and adds to existing prognostic scores.
- Published
- 2019
34. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen
- Author
-
Mendel, Arielle, Bernatsky, Sasha, Pineau, Christian A, St-Pierre, Yvan, Hanly, John G, Urowitz, Murray B, Clarke, Ann E, Romero-Diaz, Juanita, Gordon, Caroline, Bae, Sang-Cheol, Wallace, Daniel J, Merrill, Joan T, Buyon, Jill, Isenberg, David A, Rahman, Anisur, Ginzler, Ellen M, Petri, Michelle, Dooley, Mary Anne, Fortin, Paul, Gladman, Dafna D, Steinsson, Kristján, Ramsey-Goldman, Rosalind, Khamashta, Munther A, Aranow, Cynthia, Mackay, Meggan, Alarcón, Graciela, Manzi, Susan, Nived, Ola, Jönsen, Andreas, Zoma, Asad A, van Vollenhoven, Ronald F, Ramos-Casals, Manuel, Ruiz-Irastorza, Giuillermo, Lim, Sam, Kalunian, Kenneth C, Inanc, Murat, Kamen, Diane L, Peschken, Christine A, Jacobsen, Søren, Askanase, Anca, Sanchez-Guerrero, Jorge, Bruce, Ian N, Costedoat-Chalumeau, Nathalie, and Vinet, Evelyne
- Subjects
Contraception/Reproduction ,Clinical Research ,Lupus ,Autoimmune Disease ,Good Health and Well Being ,Adolescent ,Adult ,Antiphospholipid Syndrome ,Cohort Studies ,Contraceptives ,Oral ,Combined ,Contraceptives ,Oral ,Hormonal ,Contraindications ,Drug ,Drug Utilization ,Educational Status ,Female ,Humans ,Hypertension ,Lupus Erythematosus ,Systemic ,Migraine with Aura ,Practice Patterns ,Physicians' ,Registries ,Risk Factors ,Severity of Illness Index ,Young Adult ,systemic lupus erythematosus ,anti-phospholipid syndrome ,contraception ,epidemiology ,Clinical Sciences ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology - Abstract
ObjectivesTo assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.MethodsThis observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication.ResultsA total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)].ConclusionCHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure.
- Published
- 2019
35. Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort
- Author
-
Choi, May Y, Clarke, Ann E, St. Pierre, Yvan, Hanly, John G, Urowitz, Murray B, Romero‐Diaz, Juanita, Gordon, Caroline, Bae, Sang‐Cheol, Bernatsky, Sasha, Wallace, Daniel J, Merrill, Joan T, Isenberg, David A, Rahman, Anisur, Ginzler, Ellen M, Petri, Michelle, Bruce, Ian N, Dooley, Mary A, Fortin, Paul R, Gladman, Dafna D, Sanchez‐Guerrero, Jorge, Steinsson, Kristjan, Ramsey‐Goldman, Rosalind, Khamashta, Munther A, Aranow, Cynthia, Alarcón, Graciela S, Manzi, Susan, Nived, Ola, Zoma, Asad A, Vollenhoven, Ronald F, Ramos‐Casals, Manuel, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Kalunian, Kenneth C, Inanc, Murat, Kamen, Diane L, Peschken, Christine A, Jacobsen, Soren, Askanase, Anca, Stoll, Thomas, Buyon, Jill, Mahler, Michael, and Fritzler, Marvin J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lupus ,Autoimmune Disease ,Inflammatory and immune system ,Adult ,Antibodies ,Antinuclear ,Biomarkers ,Female ,Fluorescent Antibody Technique ,Indirect ,Glucocorticoids ,Humans ,Immunosuppressive Agents ,Lupus Erythematosus ,Systemic ,Male ,Mitosis ,Predictive Value of Tests ,Prognosis ,Serologic Tests ,Public Health and Health Services ,Psychology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveThe spectrum of antinuclear antibodies (ANAs) is changing to include both nuclear staining as well as cytoplasmic and mitotic cell patterns (CMPs) and accordingly a change is occurring in terminology to anticellular antibodies. This study examined the prevalence of indirect immunofluorescence (IIF) anticellular antibody staining using the Systemic Lupus International Collaborating Clinics inception cohort.MethodsAnticellular antibodies were detected by IIF on HEp-2000 substrate using the baseline serum. Three serologic subsets were examined: ANA positive (presence of either nuclear or mixed nuclear/CMP staining), anticellular antibody negative (absence of any intracellular staining), and isolated CMP staining. The odds of being anticellular antibody negative versus ANA or isolated CMP positive was assessed by multivariable analysis.ResultsA total of 1,137 patients were included; 1,049 (92.3%) were ANA positive, 71 (6.2%) were anticellular antibody negative, and 17 (1.5%) had an isolated CMP. The isolated CMP-positive group did not differ from the ANA-positive or anticellular antibody-negative groups in clinical, demographic, or serologic features. Patients who were older (odds ratio [OR] 1.02 [95% confidence interval (95% CI) 1.00, 1.04]), of white race/ethnicity (OR 3.53 [95% CI 1.77, 7.03]), or receiving high-dose glucocorticoids at or prior to enrollment (OR 2.39 [95% CI 1.39, 4.12]) were more likely to be anticellular antibody negative. Patients on immunosuppressants (OR 0.35 [95% CI 0.19, 0.64]) or with anti-SSA/Ro 60 (OR 0.41 [95% CI 0.23, 0.74]) or anti-U1 RNP (OR 0.43 [95% CI 0.20, 0.93]) were less likely to be anticellular antibody negative.ConclusionIn newly diagnosed systemic lupus erythematosus, 6.2% of patients were anticellular antibody negative, and 1.5% had an isolated CMP. The prevalence of anticellular antibody-negative systemic lupus erythematosus will likely decrease as emerging nomenclature guidelines recommend that non-nuclear patterns should also be reported as a positive ANA.
- Published
- 2019
36. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort
- Author
-
Wirestam, Lina, Enocsson, Helena, Skogh, Thomas, Padyukov, Leonid, Jönsen, Andreas, Urowitz, Murray B, Gladman, Dafna D, Romero-Diaz, Juanita, Bae, Sang-Cheol, Fortin, Paul R, Sanchez-Guerrero, Jorge, Clarke, Ann E, Bernatsky, Sasha, Gordon, Caroline, Hanly, John G, Wallace, Daniel, Isenberg, David A, Rahman, Anisur, Merrill, Joan, Ginzler, Ellen, Alarcón, Graciela S, Chatham, W Winn, Petri, Michelle, Khamashta, Munther, Aranow, Cynthia, Mackay, Meggan, Dooley, Mary Anne, Manzi, Susan, Ramsey-Goldman, Rosalind, Nived, Ola, Steinsson, Kristjan, Zoma, Asad, Ruiz-Irastorza, Guillermo, Lim, Sam, Kalunian, Ken, Inanc, Murat, van Vollenhoven, Ronald, Ramos-Casals, Manuel, Kamen, Diane L, Jacobsen, Søren, Peschken, Christine, Askanase, Anca, Stoll, Thomas, Bruce, Ian N, Wetterö, Jonas, and Sjöwall, Christopher
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Kidney Disease ,Lupus ,Clinical Research ,Inflammatory and immune system ,Adolescent ,Adult ,Age Factors ,Aged ,Asia ,Biomarkers ,Child ,Cross-Sectional Studies ,Disease Progression ,Enzyme-Linked Immunosorbent Assay ,Europe ,Female ,Follow-Up Studies ,Humans ,Internationality ,Logistic Models ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Multivariate Analysis ,North America ,Osteopontin ,Reference Values ,Severity of Illness Index ,Sex Factors ,Young Adult ,SYSTEMIC LUPUS ERYTHEMATOSUS ,BIOMARKERS ,OSTEOPONTIN ,DISEASE ACTIVITY ,ORGAN DAMAGE ,PROGNOSIS ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveIn cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes.MethodsWe included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analyzed for OPN using ELISA. Disease activity and damage were assessed at each annual followup visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively.ResultsCompared to controls, baseline OPN was raised 4-fold in SLE cases (p < 0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI ≥ 1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrollment into the cohort (r = 0.27, p < 0.0001), and patients with high disease activity (SLEDAI-2K ≥ 5) had raised serum OPN (p < 0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p = 0.0006), in cases with renal involvement (p < 0.0001) and impaired estimated glomerular filtration rate (p = 0.01).ConclusionThe performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrollment, as well as over time.
- Published
- 2019
37. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
- Author
-
Hanly, John G, Li, Qiuju, Su, Li, Urowitz, Murray B, Gordon, Caroline, Bae, Sang-Cheol, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Bernatsky, Sasha, Clarke, Ann E, Wallace, Daniel J, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Fortin, Paul R, Gladman, Dafna D, Bruce, Ian N, Petri, Michelle, Ginzler, Ellen M, Dooley, MA, Steinsson, Kristjan, Ramsey-Goldman, Rosalind, Zoma, Asad A, Manzi, Susan, Nived, Ola, Jonsen, Andreas, Khamashta, Munther A, Alarcón, Graciela S, van Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Ramos-Casals, Manuel, Lim, S Sam, Inanc, Murat, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Kamen, Diane L, Askanase, Anca, Theriault, Chris, and Farewell, Vernon
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lupus ,Clinical Research ,Autoimmune Disease ,Mental Health ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Inflammatory and immune system ,Adult ,Age Factors ,Antibodies ,Anticardiolipin ,Autoantibodies ,Cohort Studies ,Female ,Humans ,Kaplan-Meier Estimate ,Linear Models ,Lupus Coagulation Inhibitor ,Lupus Erythematosus ,Systemic ,Lupus Vasculitis ,Central Nervous System ,Male ,Middle Aged ,Proportional Hazards Models ,Prospective Studies ,Psychotic Disorders ,Receptors ,N-Methyl-D-Aspartate ,Sex Factors ,Young Adult ,beta 2-Glycoprotein I ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo determine, in a large, multiethnic/multiracial, prospective inception cohort of patients with systemic lupus erythematosus (SLE), the frequency, attribution, clinical, and autoantibody associations with lupus psychosis and the short- and long-term outcomes as assessed by physicians and patients.MethodsPatients were evaluated annually for 19 neuropsychiatric (NP) events including psychosis. Scores on the Systemic Lupus Erythematosus Disease Activity Index 2000, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, and the Short Form 36 (SF-36) were recorded. Time to event and linear regressions were used as appropriate.ResultsOf 1,826 SLE patients, 88.8% were female and 48.8% were Caucasian. The mean ± SD age was 35.1 ± 13.3 years, the mean ± SD disease duration was 5.6 ± 4.2 months, and the mean ± SD follow-up period was 7.4 ± 4.5 years. There were 31 psychotic events in 28 of 1,826 patients (1.53%), and most patients had a single event (26 of 28 [93%]). In the majority of patients (20 of 25 [80%]) and events (28 of 31 [90%]), psychosis was attributed to SLE, usually either in the year prior to or within 3 years of SLE diagnosis. Positive associations (hazard ratios [HRs] and 95% confidence intervals [95% CIs]) with lupus psychosis were previous SLE NP events (HR 3.59 [95% CI 1.16-11.14]), male sex (HR 3.0 [95% CI 1.20-7.50]), younger age at SLE diagnosis (per 10 years) (HR 1.45 [95% CI 1.01-2.07]), and African ancestry (HR 4.59 [95% CI 1.79-11.76]). By physician assessment, most psychotic events resolved by the second annual visit following onset, in parallel with an improvement in patient-reported SF-36 summary and subscale scores.ConclusionPsychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has a significant negative impact on health status. As determined by patient and physician report, the short- and long-term outlooks are good for most patients, although careful follow-up is required.
- Published
- 2019
38. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
- Author
-
Hanly, John G, Li, Qiuju, Su, Li, Urowitz, Murray B, Gordon, Caroline, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Bernatsky, Sasha, Clarke, Ann E, Wallace, Daniel J, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Fortin, Paul, Gladman, Dafna D, Bruce, Ian N, Petri, Michelle, Ginzler, Ellen M, Dooley, MA, Steinsson, Kristjan, Ramsey‐Goldman, Rosalind, Zoma, Asad A, Manzi, Susan, Nived, Ola, Jonsen, Andreas, Khamashta, Munther A, Alarcón, Graciela S, Chatham, Winn, Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Ramos‐Casals, Manuel, Lim, S Sam, Inanc, Murat, Kalunian, Kenneth C, Jacobsen, Soren, Peschken, Christine A, Kamen, Diane L, Askanase, Anca, Theriault, Chris, and Farewell, Vernon
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Autoimmune Disease ,Clinical Research ,Lupus ,Hematology ,Stroke ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Inflammatory and immune system ,Adult ,Cerebrovascular Disorders ,Female ,Humans ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Prospective Studies ,Quality of Life ,Young Adult ,Clinical Sciences ,Public Health and Health Services ,Psychology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveTo determine the frequency, characteristics, and outcomes of cerebrovascular events (CerVEs), as well as clinical and autoantibody associations in a multiethnic/racial inception cohort of patients with systemic lupus erythematosus (SLE).MethodsA total of 1,826 patients were assessed annually for 19 neuropsychiatric (NP) events, including 5 types of CerVEs: 1) stroke, 2) transient ischemia, 3) chronic multifocal ischemia, 4) subarachnoid/intracranial hemorrhage, and 5) sinus thrombosis. Global disease activity (Systemic Lupus Erythematosus Disease [SLE] Activity Index 2000), damage scores (SLE International Collaborating Clinics/American College of Rheumatology Damage Index), and Short Form 36 (SF-36) scores were collected. Time to event, linear and logistic regressions, and multistate models were used as appropriate.ResultsCerVEs were the fourth most frequent NP event: 82 of 1,826 patients had 109 events; of these events, 103 were attributed to SLE, and 44 were identified at the time of enrollment. The predominant events were stroke (60 of 109 patients) and transient ischemia (28 of 109 patients). CerVEs were associated with other NP events attributed to SLE, non-SLE-attributed NP events, African ancestry (at US SLICC sites), and increased organ damage scores. Lupus anticoagulant increased the risk of first stroke and sinus thrombosis and transient ischemic attack. Physician assessment indicated resolution or improvement in the majority of patients, but patients reported sustained reduction in SF-36 summary and subscale scores following a CerVE.ConclusionCerVEs, the fourth most frequent NP event in SLE, are usually attributable to lupus. In contrast to good physician-reported outcomes, patients reported a sustained reduction in health-related quality of life following a CerVE.
- Published
- 2018
39. Evaluating the Construct of Damage in Systemic Lupus Erythematosus
- Author
-
Johnson, Sindhu R., Gladman, Dafna D., Brunner, Hermine I., Isenberg, David, Clarke, Ann E., Barber, Megan R. W., Arnaud, Laurent, Fortin, Paul R., Mosca, Marta, Voskuyl, Alexandre E., Manzi, Susan, Aranow, Cynthia, Askanase, Anca, Alarcón, Graciela S., Bae, Sang‐Cheol, Costedoat‐Chalumeau, Nathalie, English, Jessica A., Pons‐Estel, Guillermo J., Pons‐Estel, Bernardo A., Gilman, Rebecca, Ginzler, Ellen M., Hanly, John G., Jacobsen, Soren, Kalunian, Kenneth, Kamen, Diane L., Lambalgen, Chynace, Legge, Alexandra, Lim, S. Sam, Mak, Anselm, Morand, Eric F., Peschken, Christine A., Petri, Michelle, Rahman, Anisur, Ramsey‐Goldman, Rosalind, Reynolds, John A., Romero‐Diaz, Juanita, Ruiz‐Irastorza, Guillermo, Sanchez‐Guerrero, Jorge, Svenungsson, Elisabet, Touma, Zahi, Urowitz, Murray, Vinet, Evelyne, van Vollenhoven, Ronald F., Waldhauser, Heather, Wallace, Daniel J., Zoma, Asad, and Bruce, Ian N.
- Published
- 2023
- Full Text
- View/download PDF
40. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
- Author
-
Appenzeller, Simone, Aranow, Cynthia, Askanase, Anca, Avcin, Tadej, Bae, Sang-Cheol, Bertsias, George, Bonfa, Eloisa, Cairoli, Ernesto, Cardiel, Mario H, Cervera, Ricard, Chasset, François, Chizzolini, Carlo, Clarke, Ann E, Conti, Fabrizio, Costedoat-Chalumeau, Nathalie, Czirják, László, Doria, Andrea, Dörner, Thomas, Espinosa, Gerard, Fischer-Betz, Rebecca, Garcìa, Mercedes, Gladman, Dafna D, González, Luis A, Gunnarsson, Iva, Hamijoyo, Laniyati, Hanly, John G, Hasni, Sarfaraz A, Houssiau, Frédéric A, Inanç, Murat, Inês, Luís S, Isenberg, David, Jacobsen, Soren, Jan Wu, Yeong-Jian, Kaneko, Yuko, Katsumata, Yasuhiro, Lau, Chak S, Legge, Alexandra C, Lerang, Karoline, Limper, Maarten, Louthrenoo, Worawit, Luo, Shue-Fen, Marinho, António, Massardo, Loreto, Mathian, Alexis, Mosca, Marta, Nikpour, Mandana, Pego-Reigosa, José M, Peschken, Christine A, Pons-Estel, Bernardo A, Pons-Estel, Guillermo J, Rahman, Anisur, Rednic, Simona, Ribi, Camillo, Ruiz-Irastorza, Guillermo, Sato, Emilia I, Saxena, Amit, Schneider, Matthias, Sebastiani, Gian Domenico, Strand, Vibeke, Svenungsson, Elisabet, Tanaka, Yoshiya, Tazi Mezalek, Zoubida, Tee, Michael L, Tincani, Angela, Touma, Zahi, Troldborg, Anne, Vasconcelos, Carlos, Vinet, Évelyne, Vital, Edward M, Voskuyl, Alexandre E, Voss, Anne, Wallace, Daniel, Ward, Michael, Zamora, Leonid D, Piga, Matteo, Chessa, Elisabetta, Morand, Eric F, Ugarte-Gil, Manuel F, Tektonidou, Maria, van Vollenhoven, Ronald, Petri, Michelle, and Arnaud, Laurent
- Published
- 2022
- Full Text
- View/download PDF
41. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
- Author
-
Gladman, Dafna D., Coates, Laura C., Wu, Joseph, Fallon, Lara, Bacci, Elizabeth D., Cappelleri, Joseph C., Bushmakin, Andrew G., and Helliwell, Philip S.
- Published
- 2022
- Full Text
- View/download PDF
42. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
- Author
-
Gladman, Dafna D., Mease, Philip J., Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Xu, Stephen, Quinn, Sean T., Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S., Kavanaugh, Arthur, Deodhar, Atul, Østergaard, Mikkel, and Baraliakos, Xenofon
- Published
- 2022
- Full Text
- View/download PDF
43. Metrics in Disease Activity Measures in Systemic Lupus Erythematosus
- Author
-
Tselios, Konstantinos, Gladman, Dafna D., Urowitz, Murray B., and Touma, Zahi, editor
- Published
- 2021
- Full Text
- View/download PDF
44. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
- Author
-
Strand, Vibeke, Kaeley, Gurjit S, Bergman, Martin J, Gladman, Dafna D, Coates, Laura C, Sherif, Bintu, Hur, Peter, Parikh, Bhumik, Gilloteau, Isabelle, and Mease, Philip J
- Published
- 2022
- Full Text
- View/download PDF
45. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
- Author
-
Mease, Philip J, Gladman, Dafna D, Merola, Joseph F, Nash, Peter, Grieve, Stacy, Laliman-Khara, Victor, Willems, Damon, Taieb, Vanessa, Prickett, Adam R, and Coates, Laura C
- Subjects
- *
THERAPEUTIC use of immunoglobulins , *THERAPEUTIC use of monoclonal antibodies , *MEDICAL information storage & retrieval systems , *ANTI-inflammatory agents , *PATIENT safety , *PSORIATIC arthritis , *LEFLUNOMIDE , *METHOTREXATE , *ANTIRHEUMATIC agents , *META-analysis , *DESCRIPTIVE statistics , *SYSTEMATIC reviews , *ODDS ratio , *MEDLINE , *JANUS kinases , *PHOSPHODIESTERASE inhibitors , *DRUG efficacy , *MEDICAL databases , *SULFONAMIDES , *NEUROTRANSMITTER uptake inhibitors , *INTERLEUKINS , *CHEMICAL inhibitors - Abstract
Objectives To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b/tsDMARDs) for PsA using network meta-analysis (NMA). Methods A systematic literature review (most recent update conducted on 1 January 2023) identified randomized controlled trials (RCTs) of b/tsDMARDs in PsA. Bayesian NMAs were conducted for efficacy outcomes at Weeks 12–24 for b/tsDMARD-naïve and TNF inhibitor (TNFi)-experienced patients. Safety at Weeks 12–24 was analysed in a mixed population. Odds ratios (ORs) and differences of mean change with the associated 95% credible interval (CrI) were calculated for the best-fitting models, and the surface under the cumulative ranking curve (SUCRA) values were calculated to determine relative rank. Results The NMA included 41 RCTs for 22 b/tsDMARDs. For minimal disease activity (MDA), bimekizumab ranked 1st in b/tsDMARD-naïve patients and 2nd in TNFi-experienced patients. In b/tsDMARD-naïve patients, bimekizumab ranked 6th, 5th and 3rd for ACR response ACR20/50/70, respectively. In TNFi-experienced patients, bimekizumab ranked 1st, 2nd and 1st for ACR20/50/70, respectively. For Psoriasis Area and Severity Index 90/100, bimekizumab ranked 2nd and 1st in b/tsDMARD-naïve patients, respectively, and 1st and 2nd in TNFi-experienced patients, respectively. Bimekizumab was comparable to b/tsDMARDs for serious adverse events. Conclusion Bimekizumab ranked favourably among b/tsDMARDs for efficacy on joint, skin and MDA outcomes, and showed comparable safety, suggesting it may be a beneficial treatment option for patients with PsA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study.
- Author
-
Remalante-Rayco, Patricia, Espiritu, Adrian I, Daghistani, Yassir, Chim, Tina, Atenafu, Eshetu, Keshavarzi, Sareh, Jha, Mayank, Gladman, Dafna D, Oh, Jiwon, Haroon, Nigil, and Inman, Robert D
- Subjects
INFLAMMATORY bowel disease diagnosis ,RISK assessment ,PSORIATIC arthritis ,PREDICTION models ,ANKYLOSIS ,SMOKING ,SCIENTIFIC observation ,DESCRIPTIVE statistics ,LONGITUDINAL method ,DEMYELINATION ,SPONDYLOARTHROPATHIES ,CONFIDENCE intervals ,PROPORTIONAL hazards models ,DISEASE risk factors - Abstract
Objectives The objectives of this study were to investigate the incidence of demyelinating disease (DD) among SpA patients and to identify risk factors that predict DD in this patient population. Methods Axial SpA (axSpA) and PsA patients were identified from a longitudinal cohort database. Each group was analysed according to the presence or absence of DD. Incidence rates (IRs) of DD were obtained, with competing risk analysis. Cox regression analysis (with Fine and Gray's method) was used to evaluate predictors of DD development. Results Among 2260 patients with follow-up data, we identified 18 DD events, corresponding to an average IR of 31 per 100 000 persons per year for SpA. The IR of DD at 20 years was higher in axSpA than in PsA (1.30% vs 0.13%, P = 0.01). The risk factors retained in the best predictive model for DD development included ever- (vs never-) smoking [hazard ratio (HR) 2.918, 95% CI 1.037–8.214, P = 0.0426], axSpA (vs PsA) (HR 8.790, 95% CI 1.242–62.182, P = 0.0294) and presence (vs absence) of IBD (HR 5.698, 95% CI 2.083–15.589, P = 0.0007). History of TNF-α inhibitor therapy was not a predictor of DD. Conclusion The overall incidence of DD in this SpA cohort was low. Incident DD was higher in axSpA than in PsA. A diagnosis of axSpA, the presence of IBD, and ever-smoking predicted the development of DD. History of TNF-α inhibitor use was not found to be a predictor of DD in this cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials
- Author
-
Mease, Philip J., Gladman, Dafna D., Kavanaugh, Arthur, McGonagle, Dennis, Nash, Peter, Guerette, Benoit, Nakasato, Priscila, Brunori, Michele, Teng, Lichen, and McInnes, Iain B.
- Published
- 2021
- Full Text
- View/download PDF
48. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
- Author
-
Strand, Vibeke, Mease, Philip J., Soriano, Enrique R., Kishimoto, Mitsumasa, Salvarani, Carlo, Saffore, Christopher D., Zueger, Patrick, McDearmon-Blondell, Erin, Kato, Koji, and Gladman, Dafna D.
- Published
- 2021
- Full Text
- View/download PDF
49. Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach
- Author
-
Barber, Megan RW, Hanly, John G, Su, Li, Urowitz, Murray B, St. Pierre, Yvan, Romero‐Diaz, Juanita, Gordon, Caroline, Bae, Sang‐Cheol, Bernatsky, Sasha, Wallace, Daniel J, Isenberg, David A, Rahman, Anisur, Ginzler, Ellen M, Petri, Michelle, Bruce, Ian N, Fortin, Paul R, Gladman, Dafna D, Sanchez‐Guerrero, Jorge, Ramsey‐Goldman, Rosalind, Khamashta, Munther A, Aranow, Cynthia, Mackay, Meggan, Alarcón, Graciela S, Manzi, Susan, Nived, Ola, Jönsen, Andreas, Zoma, Asad A, Vollenhoven, Ronald F, Ramos‐Casals, Manuel, Ruiz‐Irastorza, Guillermo, Lim, S Sam, Kalunian, Kenneth C, Inanc, Murat, Kamen, Diane L, Peschken, Christine A, Jacobsen, Soren, Askanase, Anca, Theriault, Chris, Farewell, Vernon, and Clarke, Ann E
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Clinical Sciences ,Lupus ,Kidney Disease ,Autoimmune Disease ,Clinical Research ,Burden of Illness ,Renal and urogenital ,Adult ,Cohort Studies ,Female ,Health Care Costs ,Humans ,Lupus Nephritis ,Male ,Middle Aged ,Models ,Economic ,Young Adult ,Public Health and Health Services ,Psychology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveLittle is known about the long-term costs of lupus nephritis (LN). The costs were compared between patients with and without LN using multistate modeling.MethodsPatients from 32 centers in 11 countries were enrolled in the Systemic Lupus International Collaborating Clinics inception cohort within 15 months of diagnosis and provided annual data on renal function, hospitalizations, medications, dialysis, and selected procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology classification criteria. Renal function was assessed annually using the estimated glomerular filtration rate (GFR) or estimated proteinuria. A multistate model was used to predict 10-year cumulative costs by multiplying annual costs associated with each renal state by the expected state duration.ResultsA total of 1,545 patients participated; 89.3% were women, the mean ± age at diagnosis was 35.2 ± 13.4 years, 49% were white, and the mean followup duration was 6.3 ± 3.3 years. LN developed in 39.4% of these patients by the end of followup. Ten-year cumulative costs were greater in those with LN and an estimated glomerular filtration rate (GFR) 60 ml/minute) or with LN and estimated proteinuria >3 gm/day ($84,040 versus $20,499 if no LN and estimated proteinuria
- Published
- 2018
50. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort
- Author
-
Little, Jayne, Parker, Ben, Lunt, Mark, Hanly, John G, Urowitz, Murray B, Clarke, Ann E, Romero-Diaz, Juanita, Gordon, Caroline, Bae, Sang-Cheol, Bernatsky, Sasha, Wallace, Daniel J, Merrill, Joan T, Buyon, Jill, Isenberg, David A, Rahman, Anisur, Ginzler, Ellen M, Petri, Michelle, Dooley, Mary Anne, Fortin, Paul, Gladman, Dafna D, Steinsson, Kristjan, Ramsey-Goldman, Rosalind, Khamashta, Munther A, Aranow, Cynthia, Mackay, Meggan, Alarcón, Graciela S, Manzi, Susan, Nived, Ola, Jönsen, Andreas, Zoma, Asad A, van Vollenhoven, Ronald F, Ramos-Casals, Manuel, Ruiz-Irastorza, Guillermo, Lim, Sung Sam, Kalunian, Kenneth C, Inanc, Murat, Kamen, Diane L, Peschken, Christine A, Jacobsen, Soren, Askanase, Anca, Sanchez-Guerrero, Jorge, and Bruce, Ian N
- Subjects
Autoimmune Disease ,Clinical Research ,Lupus ,Inflammatory and immune system ,Good Health and Well Being ,Adult ,Algorithms ,Asia ,Cross-Sectional Studies ,Disease Progression ,Dose-Response Relationship ,Drug ,Drug Prescriptions ,Ethnicity ,Europe ,Female ,Follow-Up Studies ,Glucocorticoids ,Health Status ,Humans ,International Cooperation ,Lupus Erythematosus ,Systemic ,Male ,Morbidity ,North America ,Retrospective Studies ,Risk Factors ,Severity of Illness Index ,Time Factors ,Young Adult ,systemic lupus erythematosus ,glucocorticoids ,epidemiology ,Clinical Sciences ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology - Abstract
ObjectivesTo describe glucocorticoid (GC) use in the SLICC inception cohort and to explore factors associated with GC use. In particular we aimed to assess temporal trends in GC use and to what extent physician-related factors may influence use.MethodsPatients were recruited within 15 months of diagnosis of SLE from 33 centres between 1999 and 2011 and continue to be reviewed annually. Descriptive statistics were used to detail oral and parenteral GC use. Cross sectional and longitudinal analyses were performed to explore factors associated with GC use at enrolment and over time.ResultsWe studied 1700 patients with a mean (s.d.) follow-up duration of 7.26 (3.82) years. Over the entire study period, 1365 (81.3%) patients received oral GCs and 447 (26.3%) received parenteral GCs at some point. GC use was strongly associated with treatment centre, age, race/ethnicity, sex, disease duration and disease activity. There was no change in the proportion of patients on GCs or the average doses of GC used over time according to year of diagnosis.ConclusionGCs remain a cornerstone in SLE management and there have been no significant changes in their use over the past 10-15 years. While patient and disease factors contribute to the variation in GC use, between-centre differences suggest that physician-related factors also contribute. Evidence-based treatment algorithms are needed to inform a more standardized approach to GC use in SLE.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.